HomeABVX • EPA
add
Abivax SA
Nakaraang pagsara
€104.00
Sakop ng araw
€102.60 - €106.60
Sakop ng taon
€4.51 - €132.00
Market cap
8.13B EUR
Average na Volume
170.32K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
| (EUR) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | 639.00K | -52.70% |
Gastos sa pagpapatakbo | 81.35M | 57.84% |
Net na kita | -153.36M | -177.69% |
Net profit margin | -24.00K | -487.10% |
Kita sa bawat share | — | — |
EBITDA | -80.63M | -60.84% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (EUR) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 589.70M | — |
Kabuuang asset | 652.05M | — |
Kabuuang sagutin | 140.81M | — |
Kabuuang equity | 511.24M | — |
Natitirang share | 77.83M | — |
Presyo para makapag-book | 15.83 | — |
Return on assets | -52.29% | — |
Return on capital | -63.49% | — |
Cash Flow
Net change in cash
| (EUR) | Set 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -153.36M | -177.69% |
Cash mula sa mga operasyon | -71.28M | -101.46% |
Cash mula sa pag-invest | 3.28M | 87.64% |
Cash mula sa financing | 603.46M | 9,695.50% |
Net change in cash | 528.76M | 1,362.97% |
Malayang cash flow | -71.38M | — |
Tungkol
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Itinatag
Dis 4, 2013
Website
Mga Empleyado
67
